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Background: Breast cancer is a major health problem that threatens the lives of millions of women worldwide
each year. Most of the chemotherapeutic agents that are currently used to treat this complex disease are highly
toxic with long-term side effects. Therefore, novel generation of anti-cancer drugs with higher efficiency and
specificity are urgently needed.
Methods: Breast cancer cell lines were treated with eugenol and cytotoxicity was measured using the WST-1
reagent, while propidium iodide/annexinV associated with flow cytometry was utilized in order to determine the
induced cell death pathway. The effect of eugenol on apoptotic and pro-carcinogenic proteins, both in vitro and in
tumor xenografts was assessed by immunoblotting. While RT-PCR was used to determine eugenol effect on the
E2F1 and survivin mRNA levels. In addition, we tested the effect of eugenol on cell proliferation using the real-time
cell electronic sensing system.
Results: Eugenol at low dose (2 μM) has specific toxicity against different breast cancer cells. This killing effect was
mediated mainly through inducing the internal apoptotic pathway and strong down-regulation of E2F1 and its
downstream antiapoptosis target survivin, independently of the status of p53 and ERα. Eugenol inhibited also
several other breast cancer related oncogenes, such as NF-κB and cyclin D1. Moreover, eugenol up-regulated the
versatile cyclin-dependent kinase inhibitor p21WAF1 protein, and inhibited the proliferation of breast cancer cells in a
p53-independent manner. Importantly, these anti-proliferative and pro-apoptotic effects were also observed in vivo
in xenografted human breast tumors.
Conclusion: Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used
to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for
the less responsive triple-negative subtype of the disease.
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Breast cancer remains a worldwide public health con-
cern and a major cause of morbidity and mortality
among females [1]. Treatment of breast cancer includes,
tumor resection, radiation, endocrine therapy, cytotoxic
chemotherapy and antibody-based therapy [2]. However,
resistance to these forms of therapies and tumor recur-
rence are very frequent. Furthermore, there is relative
lack of effective therapies for advanced-stage and some
forms of the disease such as triple negative breast cancer
(TNBC). Recently, PARP inhibitors showed promising* Correspondence: aboussekhra@kfshrc.edu.sa
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reproduction in any medium, provided the orresults against tumors with mutated BRCA1 and TNBC
[3,4]. Therefore, scientists keep seeking for new agents
with higher efficiency and less side effects. Of 121 pre-
scription drugs in use for cancer treatment, 90 are de-
rived from plant species and 74% of these drugs were
discovered by investigating a folklore claim [5,6]. Indeed,
several natural products and dietary constitutes exhibit
anti-cancer properties without considerable adverse ef-
fects [7,8]. Therefore, the abundance of flavonoids and re-
lated polyphenols in the plant kingdom makes it possible
that several hitherto uncharacterized agents with chemo-
preventive or chemotherapeutic effects are still to be iden-
tified. Several of these products such as curcumin, greenl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the treatment of various forms of cancer [9].
Eugenol (4-allyl (−2-mthoxyphenol)), a phenolic nat-
ural compound available in honey and in the essential
oils of different spices such as Syzgium aromaticum
(clove), Pimenta racemosa (bay leaves), and Cinnamo-
mum verum (cinnamon leaf ), has been exploited for
various medicinal applications. It serves as a weak anaes-
thetic and has been used by dentists as a pain reliever
and cavity filling cement (“clove oil”). In Asian countries,
eugenol has been used as antiseptic, analgesic and anti-
bacterial agent [10]. In addition, eugenol has antiviral
[11], antioxidant [12] and anti-inflamatory functions.
Furthermore, while it has been proved not to be carcino-
genic neither mutagenic [13], eugenol has several anti-
cancer properties. Indeed, eugenol has antiproliferative
effects in diverse cancer cell lines as well as in B16 mel-
anoma xenograft model [14-16]. Eugenol induced apop-
tosis in various cancer cells, including mast cells [17],
melanoma cells [15] and HL-60 leukemia cells [18].
Moreover, eugenol induced apoptosis and inhibited inva-
sion and angiogenesis in a rat model of gastric carcino-
genesis induced by MNNG [19]. Interestingly, Eugenol is
listed by the Food and Drug Administration (FDA) as
“Generally Regarded as Safe” when consumed orally, in
unburned form.
In the present paper we present clear evidence that eu-
genol has potent anti-breast cancer properties both




Animal experiments were approved by the KFSH & RC
institutional Animal Care and Use Committee (ACUC)
and were conducted according to relevant national and
international guidelines. Animals suffered only minimal
pain due to needle injection and certain degree of dis-
tress related to the growth/burden of the tumor. Euthan-
asia was performed using CO2 chamber.
Cell lines, chemicals and cell culture
All cell lines were purchased from the American Type
Culture Collection (ATCC) and cultured according to
ATCC instructions. The p53 and ER-α status of these
cells are mentioned in Table 1. MCF7, T47-D and MDA-Table 1 Features of used cell lines
Cell lines p53 status ER-α LC50 (μM)
MDA-MB-231 mutant negative 1.7
MCF7 wild-type positive 1.5
T47-D wild-type positive 0.9
MCF 10A wild-type positive 2.2MB-231 were maintained in RPMI-1640 (Gibco, Grand
Island, NY, USA), L-glutamine 1%, 10% fetal bovine serum
(FBS), 1% antibiotic/anti-mycotic (penicillin/streptomycin)
(Sigma Aldrich, St Louis, MO, USA). MCF 10A cells were
cultured in universal medium: (1:1 mixture of Dulbecco’s
Modified Eagles Medium (DMEM) and Ham’s F12
medium (Gibco) supplemented with 5% FBS, 1% antibiotic
antimycotic, 20 ng/ml epidermal growth factor (EGF),
100 ng/ml choleratoxin, 10 μg/ml insulin, and 500 ng/ml
hydrocortisone). Cells were maintained at 37°C in humidi-
fied incubator with 5% CO2. Eugenol (Sigma) was diluted
in DMSO and prepared at 1 mM.
Cytotoxicity assay
Cells were seeded into 96-well plates at 0.5-1.104/well
and incubated overnight. The medium was replaced with
fresh one containing the desired concentrations of eu-
genol. After 20 hrs, 10 μl of the WST-1 reagent (Roche
Diagnostics, Mannheim, Germany) was added to each
well and the plates were incubated for 4 hrs at 37°C.
The amount of formazan was quantified using ELISA
reader at 450 nm of absorbance.
Cell proliferation analysis
Complete medium (100 μl) containing 2–4 x 103 cells
was loaded in each well of the 96-well microtiter E-
plates with integrated microelectronic sensor arrays at
the bottom of each well. The plate was incubated for at
least 30 min in a humidified, 37°C, 5% CO2 incubator,
and then was inserted into the Real-Time Cell Electronic
Sensing System (RT-CES system, xCELLigence system
from Roche Applied Science, originally invented by the
US company ACEA Biosciences Inc., San Diego, CA).
This allows for label-free and dynamic monitoring of cell
proliferation. Cells were monitored for 90 hrs. The elec-
tronic readout, cell-sensor impedance is displayed as arbi-
trary units called cell index, which is defined as Rn-Rb/Rb,
with Rn = cell-electrode impedance of the well with the
cells and Rb = the background impedance of the well with
the media alone.
Cellular lysate preparation
Cells were washed with PBS and then scraped in RIPA
buffer (150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40,
0.5% Sodium deoxycolate, 0.1% SDS, 50 mM Tris–HCl
(pH 7.5)), supplemented with protease inhibitors. Lysates
were homogenized and then centrifuged at 14000 r.p.m
at 4°C for 15 min in an eppendorf micro centrifuge.
The supernatant was removed, aliquoted and stored
at −80°C.
Immunoblotting
SDS-PAGE was performed using 12% separating mini-
gels and equal amount of proteins were loaded. After
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difluroide membrane (PVDF), the membrane was incu-
bated overnight with the appropriate antibodies:
E2F1 (KH95), Survivin (D-8), NF-κB (F-6), p21 (F-5),
Bax (B-9), Bcl-2 (C-2), Cyclin D1 (HD11), caspase-9 (F-7),
Cox-2 (29), and β-Catenin (9 F2) were purchased from
Santa Cruz, Biotechnology (Santa Cruz, CA, USA);
Cleaved caspase-3 (Asp175), Cleaved caspase-9 (Asp
315), Cleaved-PARP-1 (ASP 214), Cytochrome C and
GAPDH were purchased from Cell Signaling (Danvers,
MA, USA).
Visualization of the second antibody was performed
using the superSignal West Pico Chemiluminescent sub-
strate according to the manufacturer’s recommendations
(THERMO Scientific, Rockford, IL).
RNA extraction, cDNA synthesis and RT-PCR
Total RNA was extracted using the Tri® Reagent (Sigma)
and the yield was quantitated spectrophotometrically. Fol-
lowing the manufacturer’s instructions, single stranded
cDNA was synthesized using 200 ng of total RNA, the
MMLV Reverse Transcriptase and the oligo dT18 (Roche,
San Francisco, CA, USA). The cDNA was amplified for
40 cycles under the following conditions: melting
temperature (95°C) for 50 seconds, annealing temperature
(54°C) for 50 seconds, and extension temperature (72°C)
for 1 min. The RT-PCR products were separated by elec-
trophoresis on a 2% agarose gel at 80 V for an hour. The
sequences of the primers were as follow:
β-actin, Fw:5′- CCCAGCACAATGAAGATCAAGAT
CAT; Rv: 5′-ATCTGCTGGAAGGTGGACAGCGA.
Survivin, Fw: 5′- CAGAGGAGGCGCCAAGACAG;
Rv: 5′-CCTGACGGCGGAAAACGC.
E2F1, Fw: 5′-ATGTTTTCCTGTGCCCTGAG; Rv: 5′-
ATCTGTGGTGAGGGATGAGG.
Quantification of protein and RNA expression levels
The expression levels of RNAs and proteins were measured
using the densitometer (BIO-RAD GS-800 Calibrated
Densitometer, USA). Films were scanned and protein signal
intensity of each band was determined. Next, dividing the
obtained value of each band by the values of the corre-
sponding internal control allowed the correction of the
loading differences. The fold of induction was determined
by dividing the corrected values that corresponded to the
treated samples by that of the non-treated one (time 0).
Annexin V/PI and flow cytometry
Cells were treated either with DMSO or eugenol, and
then were reincubated in complete media. Detached and
adherent cells were harvested 72 hrs later, centrifuged
and re-suspended in 1 ml PBS. Cells were then stained
by PI and Alexa Fluor 488 annexinV, using Vibrant
Apoptosis Assay kit #2 (Molecular probe, Grand Island,NY, USA). Stained cells were analyzed by flow cytome-
try. The percentage of cells was determined by the
FACScalibur apparatus and the Cell Quest Pro software
from Becton Dickinson, USA. For each cell line 3 inde-
pendent experiments were performed.
shRNA transfection
The transfection using E2F1-shRNA and control–shRNA
was performed using Lipofectamine (Life technologies,
Grand Island, NY, USA) as previously described [20].
Tumor xenografts
Breast cancer xenografts were created in 10 nude mice
by subcutaneous injection of the MDA-MB-231 cells
(5.106) into the right leg of each mouse. After the growth
of the tumors (about 2 cm3) the animals were random-
ized into 2 groups to receive intraperitoneal (i.p.) injec-
tions of eugenol (100 mg/kg) or the same volume of
DMSO each 2 days for 4 weeks. Tumor size was mea-
sured with a calliper using the following formula (Length
X Width X Height).
Results
Eugenol has cytotoxic effect on estrogen positive and
negative breast cancer cells
We first investigated the cytotoxic effect of eugenol on
different breast cancer cells (MDA-MB-231, MCF7 and
T47-D) and the non-tumorigenic MCF 10A cell line
using the WST-1 assay. Cells were seeded in triplicates
into microtiter plates and treated with increasing con-
centrations of eugenol for 24 hrs, and then the cytotoxic
effect was measured. While MCF 10A cells exhibited
high resistance to eugenol, with an LC50 (the concentra-
tion that leads to 50% survival) of 2.4 μM, breast cancer
cells showed clear sensitivity (Figure 1A). The LC50 were
1.7 μM, 1.5 μM and 0.9 μM for MDA-MB-231, MCF7
and T47-D, respectively (Figure 1A, Table 1). This indi-
cates that eugenol has differential cytotoxicity against
different breast cancer cell lines, but its less toxic against
non-neoplastic breast epithelial cells.
Eugenol triggers apoptosis in breast cancer cells through
the mitochondrial pathway independently of the
estrogen receptor status
Next, we investigated whether eugenol triggers apoptosis
in breast cancer cells. To this end, cells were treated
with different concentrations of eugenol for 3 days, and
then were stained with annexin V/Propidium Iodide
(PI), and were sorted by flow cytometry. Figure 1B
shows that eugenol triggered essentially apoptosis in
both breast cancer cells MCF7 and MDA-MB-231. How-
ever, the non-carcinogenic MCF 10A cells exhibited
great resistance. Figure 1C shows the proportions of
eugenol-induced apoptosis, which was considered as the
Figure 1 Cytotoxic effects of eugenol on breast cancer cells. (A) Exponentially growing cells were cultured in 96 well plates and treated with
the indicated concentrations of eugenol for 24 hrs. Cell death was analyzed using the WST-1 assay. The arrows indicate the LC50 for each cell line.
Error bars represent means ± S.D. (B) Cells were either sham-treated (DMSO) or challenged with the indicated concentrations of eugenol for
72 hrs, and then cell death was assessed by PI/annexinV/flow cytometery. (C) Histograms presenting the proportions of induced apoptosis in the
various cell lines. Data are presented as means ± S.D.
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the proportion of spontaneous apoptosis. Interestingly,
eugenol effect increased in a dose-dependent manner in
the 4 cell lines (Figure 1C). While the effect was only
marginal in response to 1 μM, the proportion of apop-
totic cells reached 80% in MCF7 and MDA-MB-231 and
65% in T47-D, while it was only 20% in MCF 10A in re-
sponse to 2 μM eugenol. At 4 μM, eugenol was toxic for
MCF 10A as well, and apoptosis reached 70% in these
cells, while it was beyond 80% in the three breast cancer
cell lines (Figure 1C). This indicates that the eugenol-
dependent cytotoxicity is mediated mainly through the
apoptotic cell death pathway, with selective effect on
breast cancer cells up to 2 μM. Therefore, this concen-
tration was used for the next experiments.
To confirm the induction of apoptosis by eugenol in
breast cancer cells and determine the apoptotic route
that eugenol activates, MDA-MB-231 cells were treated
with eugenol (2 μM) and were harvested after differenttime periods (0, 24, 48 and 72 hrs). Whole cell extracts
were prepared and were used to evaluate the levels of
different pro- and anti-apoptotic proteins using the im-
munoblotting technique and specific antibodies.
GAPDH was used as internal control. First, we assessed
the effect of eugenol on the caspase-3 and PARP-1 pro-
teins (two principal markers of apoptosis). Figure 2
shows that eugenol triggered the cleavage of caspase-3
and PARP-1, which led to significant increase in their
active forms, confirming the induction of apoptosis by
eugenol in breast cancer cells. Next, we assessed the ef-
fect of eugenol on the levels of Bax and Bcl-2 and have
found that while the level of Bax increased in a time-
dependent manner, the level of Bcl-2 did not change
(Figure 2). This resulted in a time-dependent increase in
the Bax/Bcl-2 ratio reaching a level 4 fold higher after
72 hrs of treatment, suggesting that eugenol triggers
apoptosis through the mitochondrial pathway. To con-
firm this, we assessed the levels of cytochrome C,
Figure 2 Eugenol triggers apoptosis through the mitochondrial
pathway. MDA-MB-231 cells were treated with eugenol (2 μM), and
then were harvested at the indicated periods of time. Proteins
(50 μg) were used for western blot analysis utilizing antibodies
against the indicated proteins. The numbers below the bands
represent the corresponding expression levels as compared with
time 0 and after normalization against GAPDH.
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that while the level of caspase-9 decreased in a time-
dependent manner reaching a level more than 3 fold lower
after 72 hrs of treatment, the level of cleaved caspase-9
and cytochrome C increased 3 fold, and 17 fold, respect-
ively (Figure 2). Together, these results demonstrate that
eugenol triggers apoptosis in breast cancer cells through
the internal mitochondrial pathway via Bax increase.
Eugenol is an efficient inhibitor of several cancer
promoting genes
To investigate the effect of eugenol on cancer-related
genes, MDA-MB-231 and MCF7 cells were either sham-
treated (DMSO) or challenged with eugenol (2 μM) for
24 hrs, and then cell lysates were prepared and protein
levels were monitored by immunoblotting. Eugenol-
treatment had strong effect on the expression of NF-κB,
decreasing its level 2 fold and 3 fold in MDA-MB-231
and MCF7, respectively (Figure 3A). Similar effect was
observed on β-catenin, indicating that eugenol could in-
hibit both major cancer promoting pathways Akt/NF-κB
and Wnt/β-catenin. To confirm this, we studied the ef-
fect of eugenol on the common downstream effector
cyclin D1 [21-23]. Indeed, eugenol treatment decreased
cyclin D1 level 3 fold in MDA-MB-231 cells and 20 foldin MCF7 cells (Figure 3A). Interestingly, the strongest
eugenol inhibitory effect was observed on E2F1 and sur-
vivin, a cancer anti-apoptosis marker [24] in both cell
lines (Figure 3A). Indeed, after 24 hrs of treatment, the
E2F1 and survivin proteins became almost undetectable
(Figure 3A). To ascertain the level of action of eugenol
on these genes, we investigated the effect on their
mRNA levels. To this end, MDA-MB-231 cells were
treated with eugenol (2 μM) for 24 hrs and total RNA
was purified and amplified using RT-PCR and specific
primers. Interestingly, eugenol treatment reduced the
expression level of both transcripts (Figure 3B). This in-
dicates that eugenol inhibits the expression of these 2
genes at the transcriptional or post-transcriptional level.
Therefore, eugenol targets several breast cancer-related
signaling pathways, leading to strong inhibition of two
important breast cancer oncogenes E2F1 and survivin in
both luminal as well as basal like breast cancer cell lines.
Eugenol triggers apoptosis through E2F1/survivin down-
regulation
To elucidate the role of eugenol-related down-regulation
of E2F1 and its antiapoptosis target survivin [25] in
apoptosis induction in breast cancer cells, we studied
the effect of E2F1 specific down-regulation on the cyto-
toxic effect of eugenol. Therefore, MDA-MB-231 cells
were transiently transfected with specific E2F1-shRNA
or control-shRNA. Figure 4A shows the effect of E2F1-
shRNA on the level of the E2F1 mRNA and protein.
Interestingly, like eugenol, E2F1 down-regulation by spe-
cific shRNA reduced also the expression level of the sur-
vivin mRNA and protein (Figure 4A). This shows that
E2F1 controls the expression of survivin in these cells.
We next treated MDA-MB-231 cells expressing either
control-shRNA or E2F1-shRNA with DMSO or eugenol
(1 μM) for 48 hrs. Figure 4B shows that 1 μM eugenol
had only marginal effect on MDA-MB-231 cells. Inter-
estingly, E2F1 down-regulation doubled the killing effect
of eugenol as compared to the effect on the correspond-
ing control cells (Figure 4B). This suggests that the kill-
ing effect of eugenol is mediated through E2F1/survivin
down-regulation.
Eugenol inhibits cell proliferation and up-regulates
p21WAF1 in breast cancer cells
Exponentially growing breast cancer cells (MDA-MB-
231, MCF7 and T47-D) were seeded in 96-well plates
and were either sham-treated with DMSO or challenged
with eugenol (2 μM), and then reincubated for 120 hrs.
During this time, the real-time cell electronic sensing
system was used to monitor cell proliferation. While
DMSO-treated cells continued to proliferate, eugenol
treatment suppressed cell proliferation in the 3 breast
cancer cell lines (Figure 5A).
Figure 3 Eugenol suppresses the expression of several oncoproteins. (A) Cells were either sham-treated (DMSO) or challenged with eugenol
(2 μM) for 24 hrs. Subsequently, cells were harvested and proteins were used for western blot analysis using the indicated antibodies. The numbers
under the bands represent the corresponding expression levels as compared to time 0 and after normalization against GAPDH. (B) DMSO- and
eugenol-treated cells (2 μM) were harvested after 4 hrs, and total RNA was extracted and subjected to RT-PCR using specific primers for the
indicated genes. The resulting products were electrophorezed in ethidium bromide stained 2% agarose gel. The numbers under the bands
represent the corresponding expression levels as compared to control (DMSO) and after normalization against β-actin.
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sion of the versatile cyclin-dependent kinase inhibitor
p21WAF1 in MDA-MB-231 and MCF7. After treatment with
eugenol (2 μM) cells were harvested at different periods of
time (0–24 hrs) and immunoblotting was utilized for pro-
tein level assessment using specific antibodies. Figure 5B
shows that eugenol increased the level of p21WAF1 reaching
a level 5 fold higher as compared to the basal level in bothFigure 4 Eugenol-dependent apoptosis is mediated through down-re
extracted from MDA-MB-231 cells expressing either control-shRNA or E2F1-
cells were treated as shown for 72 hrs, and then apoptosis was assessed by acell lines. Therefore, eugenol is a strong inducer of p21WAF1
expression in a p53-independent manner.
Eugenol inhibits tumor growth of breast tumor
xenografts in mice
To study the anti-cancer effect of eugenol in vivo, breast
cancer xenografts were created by injecting 5.106 MDA-
MB-231 cells subcutaneously into nude mice. Whengulation of E2F1 and survivin. (A) Total RNA and proteins were
shRNA and used for RT-PCR and western blot analysis. (B) MDA-MB-231
nnexinV/PI like in Figure 1B. Data are presented as means ± S.D.
Figure 5 Eugenol inhibits breast cancer cell proliferation and up-regulates p21WAF1. (A) Sub-confluent cells (2–4.103) were either
sham-treated or challenged with eugenol (2 μM) for the indicated periods of time, and cell proliferation rate was determined using the Real-Time
Cell Electronic Sensing System. (B) MDA-MB-231 and MCF7 cells were treated with eugenol (2 μM) for the indicated periods of time, and then cell
lysates were prepared and 50 μg of proteins were used for western blot analysis utilizing the indicated antibodies.
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eugenol was given i.p. at a dose of 100 mg/kg each 2 days
for 4 weeks. Control animals were treated with DMSO
only. Interestingly, in the mock-treated animals, the vol-
ume of the tumors increased in a time-dependent man-
ner and became 3 fold bigger than the initial ones
(Figure 6A). On the other hand, treatment with eugenol
inhibited tumor growth (Figure 6A). This shows that
eugenol inhibits the proliferation of breast cancer cells
in vivo as well.
Subsequently, we investigated the effect of eugenol on the
expression of various cancer-related genes in tumor xeno-
grafts. Figure 6B shows that eugenol down-regulated E2F1
and survivin in tumor xenografts as well. Concomitantly,Figure 6 Eugenol inhibits tumor growth and modulates gene express
MDA-MB-231 cells subcutaneously into nude mice. When tumors grew, eu
treated with DMSO. (A) Tumor growth. Data are presented as means ± S.D
extracts were prepared and used for immunoblotting analysis using the indthe levels of NF-κB and cyclin D1 also decreased and
Cox-2 became undetectable (Figure 6B). Interestingly, like
in vitro, eugenol up-regulated p21WAF1 (Figure 6B). Fur-
thermore, we have investigated the effect of eugenol on
the expression of apoptosis-related genes and have shown
that eugenol increased the levels of Bax, cleaved PARP-1
and the active form of caspase-9, but decreased the level
of the anti-apoptosis protein Bcl-2, suggesting eugenol-
dependent induction of apoptosis in vivo and confirming
the results obtained in vitro (Figure 6B).
Discussion
In the present study we have shown that eugenol, a nat-
ural phenolic compound, exhibits strong anti-breastion in vivo. Breast cancer xenografts were created by injecting
genol was given i.p. at a dose of 100 mg/kg. Control animals were
. (B) Following the treatments, tumors were excised and protein
icated antibodies.
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that eugenol could be considered as a potential thera-
peutic agent for both ER-negative as well as ER-positive
breast tumors for the following reasons:
First, eugenol is cytotoxic and triggered apoptosis in
great proportion of breast cancer cells, with marginal ef-
fect on normal cells in response to 2 μM of eugenol.
However, at higher concentration (4 μM), eugenol killed
normal cells as well, showing that this molecule may
have some toxicity when used as high concentrations.
Eugenol-related apoptosis was mediated through the
mitochondrial pathway via Bax increase, and is p53- and
ERα-independent since it occurred in p53- and ERα-
defective cells, MDA-MB-231 [26]. This effect was medi-
ated through strong down-regulation of E2F1 and its
antiapoptosis target survivin [25]. Indeed, specific down-
regulation of E2F1 strongly reduced the level of survivin
and increased the effect of eugenol on breast cancer cells
(Figure 4). Notably, low E2F1 levels were related to fa-
vorable breast cancer outcome [27]. On the other hand,
E2F1 expression was related with poor survival of lymph
node-positive breast cancer patients treated with fluoro-
uracil, doxorubicin and cyclophosphamide [28]. This in-
dicates that high E2F1 levels reduce the response of
breast tumors to therapy. Similarly, while survivin ex-
pression has been found to confer resistance to chemo-
therapy and radiation, targeting survivin in experimental
models improved survival [29]. Thereby, the fact that eu-
genol can inhibit both E2F1 and survivin in vitro and in
tumor xenografts, indicates that eugenol could be used
to consolidate the adjuvant treatment of breast cancer
patients, especially the clinically aggressive ER-negative
types, whose prognosis is still poor and clinically charac-
terized as more aggressive and less responsive to stand-
ard treatments [30,31].
Second, eugenol is a potent inhibitor of cell prolifera-
tion, may be through inhibition of E2F1 and great increase
in the level of the cyclin-dependent kinase inhibitor
p21WAF1 in vitro and in tumor xenografts. E2F1 is a tran-
scription factor that regulates the expression of several
genes involved in G1 to S phase transition [32]. In a previ-
ous study it has been shown that eugenol inhibits cell pro-
liferation in melanoma cells through inhibition of E2F1
[15]. p21 induction in p53-defective MDA-MB-231 cells,
suggests the ability of eugenol to induce p21WAF1 through
p53-independent mechanism. Overexpression of p21WAF1
can block both the G1/S and G2/M transitions of the
cell cycle [33]. Furthermore, p21WAF1 is a modulator of
apoptosis in a number of systems [34-36]. Therefore,
the strong eugenol-dependent up-regulation of p21WAF1
in a p53-independent manner could be of great value
for the inhibition of cancer cell proliferation and
the induction of cell death in various p53-defective
breast tumors, including the triple negative form ofthe disease where p53 deficiency is observed in up
to 44% [37].
Third, eugenol down-regulated several onco-proteins
known to be highly expressed in breast cancer cells and
tissues, such as NF-κB, β-catenin, cyclin D1, Bcl-2 and
survivin. Akt/NF-κB signaling pathway plays a major
role in breast carcinogenesis. NF-κB up-regulation is im-
plicated not only in tumor growth and progression, but
also in the resistance to chemo- and radiotherapies. Sev-
eral studies have documented the elevated activity of this
protein in breast cancer cells [38,39], which makes it an
excellent target for cancer therapy [40,41]. In a recent
study, it has been shown that eugenol can inhibit cell
proliferation via NF-κB suppression in a rat model of
gastric carcinogenesis [42]. The other important breast
cancer signaling pathway is the Wnt/β-catenin, which is
another transcription factor that has been found highly
expressed in various types of cancer, including breast car-
cinomas [43,44], and is particularly activated in triple
negative breast cancer. Therefore, the Wnt/β-catenin sig-
naling pathway constitutes an important potential thera-
peutic target in the treatment of breast cancer, especially
the triple negative form of the disease [45].
The activation of these 2 signaling pathways leads to the
up-regulation of cyclin D1, which is a common down-
stream effector protein. Cyclin D1 is an oncogene that is
over-expressed in about 50% of all breast cancer cases
[46], and its down-regulation is an important target in
breast cancer therapy [47]. Therefore, eugenol-related
down-regulation of NF-κB and β-catenin and their com-
mon downstream target cyclin D1 could have a great in-
hibitory effect on breast cancer growth. Importantly, the
inhibitory effect of eugenol on these onco-proteins was
also observed in vivo in tumor xenografts (Figure 6).
Conclusions
Eugenol could constitute a potent anti-breast cancer
agent with less side effects than the classical chemother-
apeutic agents, through targeting the E2F1/survivin
oncogenic pathway. Therefore, eugenol warrants further
investigations for its potential use as chemotherapeutic
agent against ER-negative and also p53-defective tumors,
which are still of poor prognosis.
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